Limitation of the first-line anti-tuberculosis drugs and development of new drugs
Absztrakt
The first-line treatment of tuberculosis is composed of a combination of rifampicin, pyrazinamide, isoniazid, and ethambutol. However, there are many resistance mechanisms and side effects caused by a current regimen. Because of these limitations, new drugs and regimens are under clinical trials now. They can shorten the duration of treatment and can be safer compared to the current drugs.